日本農芸化学会

The association between serum serotonin levels and overactive bladder: results from a community-based cross-sectional study in Japan.

Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

World J Urol   39 ( 1 )   169 - 175   2021.1

The association between gut microbiome and erectile dysfunction: a community- based cross-sectional study in Japan.

Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

Int Urol Nephrol   52 ( 8 )   1421 - 1428   2020.8

The association between gut microbiome and erectile dysfunction: a community-based cross-sectional study in Japan.

Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

Int Urol Nephrol   2020.3

The association between serum serotonin levels and overactive bladder: results from a community-based cross-sectional study in Japan.

Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

World J Urol   2020.3

Influence of pretreatment quality of life on prognosis in patients with urothelial carcinoma.

Suppanuntaroek S, Hatakeyama S, Fujita N, Kubota Y, Suzuki Y, Okamoto T, Tobisawa Y, Yoneyama T, Yamamoto H, Mori K, Imai A, Yoneyama T, Hashimoto Y, Ohyama C.

Int J Clin Oncol.   25 ( 2 )   362 - 369   2020.3

The Relationship Between Gait Function and Erectile Dysfunction: Results from a Community-Based Cross-Sectional Study in Japan.

Okamoto T, Hatakeyama S, Imai A, Konishi S, Okita K, Yamamoto H, Tobisawa Y, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

J Sex Med.   16 ( 12 )   1922 - 1929   2019.12

Clinical significance of the LacdiNAc-glycosylated prostate-specific antigen assay for prostate cancer detection.

Yoneyama T, Tobisawa Y, Kaneko T, Kaya T, Hatakeyama S, Mori K, Sutoh Yoneyama M, Okubo T, Mitsuzuka K, Duivenvoorden W, Pinthus JH, Hashimoto Y, Ito A, Koie T, Suda Y, Gardiner RA, Ohyama C.

Cancer Sci.   110 ( 8 )   2573 - 2589   2019.8

KK47細胞BCG生菌耐性株に対するナノパーティクルBCGの直接効果と耐性株の遺伝子発現解析

盛　和行、米山　徹、小玉　寛健、日下　歩、細越　正吾、得居　範子、山本　勇人、今井　篤、畠山　真吾、米山　高弘、橋本　安弘、古家　琢也、大山　力

泌尿器外科   31 ( 4 )   401 - 402   2018.4

Aberrant N-Glycosylation Profile of Serum Immunoglobulins is a Diagnostic Biomarker of Urothelial Carcinomas.

Tanaka T, Yoneyama T, Noro D, Imanishi K, Kojima Y, Hatakeyama S, Tobisawa Y, Mori K, Yamamoto H, Imai A, Yoneyama T, Hashimoto Y, Koie T, Tanaka M, Nishimura SI, Kurauchi S, Takahashi I, Ohyama C.

Int J Mol Sci.   18 ( 12 )   2632 - 2644   2017.12

BCG関連新規薬物療法の開発

盛　和行

日本臨床   75 ( Suppl 7 )   319 - 322   2017.10

Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant.

Noro D, Yoneyama T, Hatakeyama S, Tobisawa Y, Mori K, Hashimoto Y, Koie T, Tanaka M, Nishimura SI, Sasaki H, Saito M, Harada H, Chikaraishi T, Ishida H, Tanabe K, Satoh S, Ohyama C.

Int J Mol Sci.   18 ( 8 )   1731 - 1747   2017.8

BCG生菌double耐性株に対するナノパーティクルBCGの直接効果

盛　和行, 米山　徹, 野呂　大輔, 成田　拓磨, 田中　壽和, 萩原　和久, 及川　真亮, 今井　篤, 畠山　真吾, 米山　高弘, 橋本　安弘, 古家　琢也, 大山　力

泌尿器外科   30 ( 4 )   442 - 443   2017.4

糖鎖を標的にした前立腺癌バイオマーカーの開発と臨床応用

大山　力，米山　徹，飛澤　悠葵，石川　友一，畠山　真吾，古家　琢也，盛　和行

臨床病理   65 ( 2 )   210 - 217   2017.2

Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer

Hagiwara K, Tobisawa Y, Kaya T, Kaneko T, Hatakeyama S, Mori K, Hashimoto Y, Koie T, Suda Y, Ohyama C, Yoneyama T

Int J Mol Sci   18 ( 2 )   261 - 276   2017.1

Core 2 β-1, 6-N-acetylglucosaminyltransferase-1 expression in prostate biopsy specimen is an indicator of prostate cancer aggressiveness

Sato T, Yoneyama T, Tobisawa Y, Hatakeyama S, Yamamoto H, Kojima Y, Mikami J, Mori K, Hashimoto Y, Koie T, Ohyama C

Biochem Biophys Res Commun   2016.1

I-branching N-acetylglucosaminyltransferase regulates prostate cancer invasiveness by enhancing α5β1 integrin signaling

Mikami J, Tobisawa Y, Yoneyama T, Hatakeyama S, Mori K, Hashimoto Y, Koie T, Ohyama C, Fukuda M：

Cancer Sci   2015.12

Detection of Core2 β-1, 6-N-Acetylglucosaminyltransferase in Post-Digital Rectal Examination Urine Is a Reliable Indicator for Extracapsular Extension of Prostate Cancer

Kojima Y, Yoneyama T, Hatakeyama S, Mikami J, Sato T, Mori K, Hashimoto Y, Koie T, Ohyama C, Fukuda M, Tobisawa Y

PLoS One   2015.9

Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.

Koie T, Ohyama C, Hosogoe S, Yamamoto H, Imai A, Hatakeyama S, Yoneyama T, Hashimoto Y, Yoneyama T, Tobisawa Y, Mori K

Case Rep Urol   2015.6

Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.

Koie T, Ohyama C, Yoneyama T, Yamamoto H, Imai A, Hatakeyama S, Hashimoto Y, Yoneyama T, Tobisawa Y, Mori K

BMC Urol   15 ( 1 )   32   2015.4

Nanoparticle BCG

Kazuyuki Mori

Jpn J Urol Surg   28 ( 2 )   151 - 154   2015.2

Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer.（共著）

Yoneyama T, Ohyama C, Hatakeyama S, Narita S, Habuchi T, Koie T, Mori K, Hidari KI, Yamaguchi M, Suzuki T, Tobisawa Y

Biochem Biophys Res Commun   448 ( 4 )   390 - 396   2014.6

Outcome Comparison of ABO-Incompatible Kidney Transplantation WithLow-DoseRituximab andABO-CompatibleKidneyTransplantation:A Single-Center Experience.（共著）

1. Hatakeyama S, Fujita T, Murakami R, Suzuki Y, Sugiyama N, Yamamoto H, Okamoto A, Imai A, Tobisawa Y, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Koie T, Narumi S, Ohyama C

Transplantation Proceedings   46 ( 2 )   445 - 448   2014.3

Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity.（共著）

Okamoto T, Yoneyama MS, Hatakeyama S, Mori K, Yamamoto H, Koie T, Saitoh H, Yamaya K, Funyu T, Fukuda M, Ohyama C, Tsuboi S.

Mol Med Rep   7 ( 2 )   359 - 64   2013.2

Kidney Transplantation at Hirosaki kidney transplant unit-initial 5year experience.（共著）

Narumi S, Murakami R, Hatakeyama S, Fujita T, Koie T, Yoneyama T, Kudoh S, Ksmimura N, Mori K, Shimada M, Nakamura N, Umehara M, Saitoh H, Okumura K, Hakamada K, Ohyama C

Hirosaki Medical Journal   63 ( 2-4 )   136 - 142   2012.12

MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis. （共著）

Suzuki Y, Sutoh M, Hatakeyama S, Mori K, Yamamoto H, Koie T, Saitoh H, Yamaya K, Funyu T, Habuchi T, Arai Y, Fukuda M, Ohyama C, Tsuboi S.

Int J Oncol   40 ( 6 )   1831 - 1838   2012.7

A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans （共著）

Tsuboi S, Sutoh M, Hatakeyama S, Hiraoka N, Habuchi T, Horikawa Y, Hashimoto Y, Yoneyama T, Mori K, Koie T, Nakamura T, Saitoh H, Yamaya K, Funyu T, Fukuda M, Ohyama C.

EMBO J   30 ( 15 )   3173 - 3185   2011.7

膀胱癌における尿テロメラーゼ活性簡易測定法の有用性

岩渕　郁哉, 盛　和行他

泌尿器科紀要   56 ( 10 )   551 - 557   2010.10

Role of peroxynitrite and recombinant human manganese superoxide dismutase in reducing ischemia-reperfusion renal tissue injury

Rahman NA, Mori K, Mizukami M, Suzuki T, Takahashi N, Ohyama C

Transplantation Proceedings   41   3603 - 3610   2009.11

Protein profiling of post-prostatic massage urine specimens by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to discriminate between prostate cancer and benign lesions.（共著）

Okamoto A, Yamamoto H, Imai A, Hatakeyama S, Iwabuchi I, Yoneyama T, Hashimoto Y, Koie T, Kamimura N, Mori K, Yamaya K, Ohyama C.

Oncol Rep   21 ( 1 )   73 - 79   2009.1

Low-dose instillation therapy with bacille Calmette-Guérin Tokyo 172 strain after transurethral resection: historical cohort study（共著）

Yoneyama T, Ohyama C, Imai A, Ishimura H, Hagisawa S, Iwabuchi I, Mori K, Kamimura N, Koie T, Yamato T, Suzuki T.

Urology   71 ( 6 )   1161 - 1165   2008.6

Short-term outcome of neoadjuvant gemcitabine-carboplatin therapy for muscle-invasive bladder cancer"jointly worked"

Yamato T, Okamoto A, Imai A, Ishimura D, Hatakeyama S, Hagisawa S, Iwabuchi I, Yoneyama T, Mori K, Koie T, Ohyama C.

Gan To Kagaku Ryoho   35 ( 1 )   83 - 86   2008.1

前立腺癌—基礎・臨床研究のアップデートーII.臨床研究　診断　病期診断　臨床病期分類（共著）

大山　力,古家　琢也,盛　和行

日本臨床   65 ( Suppl10 )   285 - 288   2007.12

INVESTIGATION OF ACTIVE BACILLUS CALMETTE-GUÉRIN (BCG) COMPONENT ON BLADDER CANCER CELL LINE(jointly worked)

Yoshikawa K et al

Hirosaki Med J   59 ( 1 )   41 - 48   2007.11

被膜下前立腺摘除術（共著）

大山　力,大和　隆,米山　高弘,古家　琢也,盛　和行

臨床泌尿器科   61 ( 11 )   883 - 888   2007.10

尿路として利用された腸管の発癌性について（共著）

大山　力,米山　高弘,神村　典孝,大和　隆,古家　琢也,萩沢　茂,岩渕　郁哉,盛　和行

Urology View   5 ( 3 )   86 - 91   2007.6

Anti-tumor effects by nano particulate BCG(jointly worked)

Mori K et al

Ann Soc BCG BRM Immunother   30 ( 1 )   71 - 77   2006.12

Anti-tumor effects of subcellular frctions from Mycobacterium bovis BCG Tokyo 172 and M. phlei(jointly worked)

Mori K et al

Ann Soc BCG BRM Immunother   29 ( 1 )   59 - 68   2005.12

Direct anti-tumor effects of subcellular components of BCG-preliminary study on the particle size of effective component-(jointly worked)

Mori K et al

Ann Soc BCG BRM Immunother   28 ( 1 )   37 - 42   2004.12

Expression of nitric oxide and inducible nitric oxide synthase in acute renal allograft rejection in the rat（共著）

A Suzuki, S Kudoh, K Mori, N Takahashi, T Suzuki

Int J Urol   11 ( 10 )   833 - 844   2004.10

Anti-tumor effects of cell wall component fractionated from BCG(jointly worked)

Mori K et al

Ann Soc BCG BRM Immunother   27 ( 1 )   33 - 41   2003.12